April 20, 2024
Bio
Samsung’s sales of biosimilars hits US$257m in Europe
[THE INVESTOR] Korean pharmaceutical firm Samsung Bioepis saw its sales of biosimilar products released in Europe hit US$257 million through the third quarter of this year, data showed on Oct. 25.
Samsung Bioepis said the sales of Benepali released in Europe came to US$253 million over the January-September period, compared with US$47 million posted a year earlier.
The company also said the sales of Flixabi posted a sharp growth over the cited period to reach US$4.7 million, compared with US$100,000 tallied last year.
Accordingly, the combined shipment of biosimilar products to Europe jumped fivefold on-year.
By Alex Lee and newswires (alexlee @heraldcorp.com)
Samsung Bioepis said the sales of Benepali released in Europe came to US$253 million over the January-September period, compared with US$47 million posted a year earlier.
The company also said the sales of Flixabi posted a sharp growth over the cited period to reach US$4.7 million, compared with US$100,000 tallied last year.
Accordingly, the combined shipment of biosimilar products to Europe jumped fivefold on-year.
By Alex Lee and newswires (alexlee @heraldcorp.com)
